» Articles » PMID: 11781272

Epidemiology and Clinical Features of Cryptosporidium Infection in Immunocompromised Patients

Overview
Specialty Microbiology
Date 2002 Jan 10
PMID 11781272
Citations 169
Authors
Affiliations
Soon will be listed here.
Abstract

Cryptosporidium spp. are a major cause of diarrheal disease in both immunocompetent and immunodeficient individuals. They also cause waterborne disease in both the United States and United Kingdom. Studies on the mechanisms of immunity to cryptosporidiosis indicate the importance of the T-cell response. The spectrum and severity of disease in immunocompromised individuals with cryptosporidiosis reflect this importance since the most severe disease is seen in individuals with defects in the T-cell response. The most commonly studied group is that of patients with AIDS. These patients suffer from more severe and prolonged gastrointestinal disease that can be fatal; in addition, body systems other than the gastrointestinal tract may be affected. The widespread use of antiretroviral therapy does appear to be having a beneficial effect on recovery from cryptosporidiosis and on the frequency of infection in human immunodeficiency virus-positive patients. Other diseases that are associated with increased risk of severe cryptosporidiosis, such as primary immunodeficiencies, most notably severe combined immunodeficiency syndrome, are also predominantly associated with T-cell defects. Of the remaining groups, children with acute leukemia seem to be most at risk from cryptosporidiosis. There is less evidence of severe complications in patients with other malignant diseases or in those receiving immunosuppressive chemotherapy.

Citing Articles

Retrospective case-case study investigation of a significant increase in spp. in England and Wales, August to September 2023.

Williams S, Matthews E, Inns T, Roberts C, Matizanadzo J, Cleary P Euro Surveill. 2025; 30(9).

PMID: 40051396 PMC: 11887033. DOI: 10.2807/1560-7917.ES.2025.30.9.2400493.


Antiparasitic activity of the iron-containing milk protein lactoferrin and its potential derivatives against human intestinal and blood parasites.

Anand N Front Parasitol. 2025; 2():1330398.

PMID: 39816822 PMC: 11731944. DOI: 10.3389/fpara.2023.1330398.


Infection During Pregnancy and Effects on Pregnancy Outcomes in Israel.

Shapiro Ben David S, Snitser O, Parizade M, Orvieto N, Segal Y, Adler L Microorganisms. 2025; 12(12.

PMID: 39770775 PMC: 11678744. DOI: 10.3390/microorganisms12122572.


High Clinical Burden of spp. in Adult Patients with Acquired Immunodeficiency in Ghana.

Sarfo F, Frickmann H, Dompreh A, Asibey S, Boateng R, Weinreich F Microorganisms. 2024; 12(11).

PMID: 39597540 PMC: 11596490. DOI: 10.3390/microorganisms12112151.


Cryptosporidiosis in a Zoonotic Gastrointestinal Disorder Perspective: Present Status, Risk Factors, Pathophysiology, and Treatment, Particularly in Immunocompromised Patients.

Balendran T, Iddawela D, Lenadora S J Trop Med. 2024; 2024:6439375.

PMID: 39534184 PMC: 11557182. DOI: 10.1155/2024/6439375.


References
1.
Uga S, Kunaruk N, Rai S, Watanabe M . Cryptosporidium infection in HIV-seropositive and seronegative populations in southern Thailand. Southeast Asian J Trop Med Public Health. 1998; 29(1):100-4. View

2.
Sorvillo F, BEALL G, Turner P, Beer V, Kovacs A, Kraus P . Seasonality and factors associated with cryptosporidiosis among individuals with HIV infection. Epidemiol Infect. 1998; 121(1):197-204. PMC: 2809492. DOI: 10.1017/s0950268898001009. View

3.
Hashmey R, Smith N, Cron S, Graviss E, Chappell C, White Jr A . Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore). 1997; 76(2):118-39. DOI: 10.1097/00005792-199703000-00004. View

4.
Enriquez F, Avila C, Santos J, Vallejo O, Sterling C . Cryptosporidium infections in Mexican children: clinical, nutritional, enteropathogenic, and diagnostic evaluations. Am J Trop Med Hyg. 1997; 56(3):254-7. DOI: 10.4269/ajtmh.1997.56.254. View

5.
Nachbaur D, Kropshofer G, Feichtinger H, Allerberger F, Niederwieser D . Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2. Bone Marrow Transplant. 1997; 19(12):1261-3. DOI: 10.1038/sj.bmt.1700826. View